Despite confluent evidence of the role of caspase-6 activation and caspase-6-cleaved in AD pathogenesis [48, 54], only recently monoclonal antibodies against these tau specimens became available to directly investigate the frequency of tau D13 and D402 in tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.